DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Exatecan is an investigational drug.
There have been 16 clinical trials for Exatecan. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2001.
The most common disease conditions in clinical trials are Sarcoma, Liver Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Daiichi Sankyo Inc., National Cancer Institute (NCI), and European Organisation for Research and Treatment of Cancer - EORTC.
Recent Clinical Trials for Exatecan
|Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma||Daiichi Sankyo Inc.||Phase 2|
|Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor||Daiichi Sankyo Inc.||Phase 2|
|Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma||European Organisation for Research and Treatment of Cancer - EORTC||Phase 2|